Beneath High Ratings, MA-PD Stars Scores Show Shortcomings

Thanks to numerous flexibilities granted to plan sponsors during the COVID-19 public health emergency, nearly 70% of Medicare Advantage Prescription Drug (MA-PD) plans earned an overall rating of 4 stars or higher for 2022, CMS said on Oct. 8. That’s compared with just 49% of MA-PD plans in 2021. But the underlying data shows that quality improvements weren’t as impressive as the 2022 star ratings suggest, and with rising quality bonus payments (QBPs), the 2022 ratings could have major implications for MA revenue in the future, industry experts warn.

© 2021 MMIT

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/12/WordPress-Featured_AdobeStock_363940192.jpg
December 2

Recent MA Coding Complaints Signal DOJ’s ‘Evolving Expectations’

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/09/WordPress-Featured-Image-radar-on-medicare-advantage-With-More-Online-Enrollment-MAOs-Must-Add-‘Personal-Touch.jpg
December 2

In AEP Home Stretch, MAOs Make Final Push for Enrollment

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/12/WordPress-Featured_AdobeStock_176084659.jpg
December 2

Expecting Hot Medicare AEP, E-Brokers Beefed Up Internal Sales Forces

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today